PR Newswire Clinical TrialsOriginal article
Consano Bio Receives FDA Investigational New Drug Clearance to Expand the C-1101 Chronic Sciatica Clinical Development Program into the United States
RegulatoryapprovedC-1101Positive
AI Analysis
Summary
Consano Bio received FDA IND clearance to expand C-1101, a potential first-in-class, non-opioid, disease-modifying therapy for chronic sciatica, into US clinical development.
Clinical Trial Data
Outcome Details
FDA Investigational New Drug (IND) clearance received
Importance:6/10
Sentiment:
0.85
FDA clearanceINDchronic sciaticanon-opioidfirst-in-classdisease-modifying
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 20, 2026 12:10 PM